journal article·2022-07Open access

Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose

Kai Guo, Yixuan Liu, Min Ding, Qi Sun, Quazi T.H. Shubhra

Materials & Design· Volume 219

Abstract

In this study, it was aimed to exploit no chemical drug to treat cancer by starvation-immunotherapy combination. We used PD-L1 siRNA to down-regulate checkpoint protein PD-L1 on cancer cell surfaces, and IFN-γ was used as an immunomodulatory agent to activate the innate immune system. When PD-L1 siRNA, IFN-γ, and glucose oxidase (GOx) were co-delivered to the tumor microenvironment (TME) by a pH-sensitive drug delivery system (DDS), starvation-immunotherapy combinedly resulted in significant tumor volume reduction in a mouse model. The DDS was prepared by using PLGA polymer whose surface was coated with chitosan. IFN-γ, siRNA, and GOx entrapment efficiencies were 93.5 ± 3.1%, 65.1 ± 2.6%, and 66.2 ± 3.3%, respectively. Moreover, the size of the DDS was well below 200 nm, allowing easy sterilization and tumor accumulation by the enhanced permeability and retention (EPR) effect. In vitro pH-dependent release study indicated that in acidic pH, the developed DDS can show accelerated drug release. In a mouse model and in acidic TME, the DDS resulted in the best therapeutic effect due to pH-dependent drug release compared to unmodified DDS and free drug. Our findings reflect that high efficiency in colon cancer treatment is achieved by combination therapy over the studied monotherapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Engineering polymer nanoparticles using cell membrane coating technology and their application in cancer treatments: Opportunities and challenges
2. Nonepitaxial Gold-Tipped ZnSe Hybrid Nanorods for Efficient Photocatalytic Hydrogen Production
3. Metal Halide Perovskite Nanorods: Shape Matters
4. Colloidal quasi-one-dimensional dual semiconductor core/shell nanorod couple heterostructures with blue fluorescence10.1039/C9NR02443C ↗
5. Immune checkpoint inhibitors win the 2018 Nobel Prize10.1016/j.bj.2019.09.002 ↗
6. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer)10.1186/s12885-018-5020-3 ↗
7. Immune evasion in cancer: Mechanistic basis and therapeutic strategies10.1016/j.semcancer.2015.03.004 ↗
8. Biomedical Applications of Biodegradable Polymers10.1002/polb.22259 ↗
9. Effect of matrix modification by natural rubber on the performance of silk-reinforced polypropylene composites10.1177/0731684410375640 ↗
10. Mechanical and degradation characteristics of natural silk and synthetic phosphate glass fiber reinforced polypropylene composites10.1177/0021998310380290 ↗
11. Surface modified thin film from silk and gelatin for sustained drug release to heal wound10.1039/C5TB00920K ↗
12. Poloxamers for Surface Modification of Hydrophobic Drug Carriers and Their Effects on Drug Delivery10.1080/15583724.2013.862544 ↗
13. Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part I Effect of process variables on the mean size10.3109/02652048.2013.814729 ↗
14. Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery10.3390/polym11020304 ↗
15. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery10.1016/j.canlet.2017.04.008 ↗
16. Chitosan Derivatives and Their Application in Biomedicine10.3390/ijms21020487 ↗
17. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity10.1002/adma.202002197 ↗
18. Homotypic biomimetic coating synergizes chemo-photothermal combination therapy to treat breast cancer overcoming drug resistance10.1016/j.cej.2021.131120 ↗
19. Current and Future Treatment Strategies for Rhabdomyosarcoma10.3389/fonc.2019.01458 ↗
20. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice10.1016/j.lfs.2020.118847 ↗
21. Interferon gamma in cancer immunotherapy10.1002/cam4.1700 ↗
22. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines10.1158/0008-5472.CAN-12-1187 ↗
23. MnO2 Nanoflowers Induce Immunogenic Cell Death under Nutrient Deprivation: Enabling an Orchestrated Cancer Starvation-Immunotherapy10.1002/advs.202002667 ↗
24. Advances in nanomedicine for cancer starvation therapy10.7150/thno.38261 ↗
25. In vitro IFN-alpha release from IFN-alpha- and pegylated IFN-alpha-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles10.2217/nnm-2016-0058 ↗
26. Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part II Effect of process variables on protein model drug encapsulation efficiency10.3109/02652048.2013.814730 ↗
27. Calcium phosphate nanoparticles prepared from infusion fluids for stem cell transfection: process optimization and cytotoxicity analysis10.1039/C6BM00870D ↗
28. Systemic Co-delivery of drugs by a pH- and photosensitive smart nanocarrier to treat cancer by chemo-photothermal-starvation combination therapy
29. Preliminary in vivo magnetofection data using magnetic calcium phosphate nanoparticles immobilizing DNA and iron oxide nanocrystals10.1016/j.dib.2018.04.058 ↗
30. Dual targeting smart drug delivery system for multimodal synergistic combination cancer therapy with reduced cardiotoxicity10.1016/j.actbio.2021.06.016 ↗
31. Acidity generated by the tumor microenvironment drives local invasion10.1158/0008-5472.CAN-12-2796 ↗
32. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles10.1016/j.ejpb.2008.06.008 ↗
33. Surface modification of HSA containing magnetic PLGA nanoparticles by poloxamer to decrease plasma protein adsorption10.1016/j.colsurfb.2014.07.025 ↗
34. Preparation of PLGA-chitosan based nanocarriers for enhancing antibacterial effect of ciprofloxacin in root canal infection10.1080/10717544.2019.1701140 ↗
35. A Chitosan-PLGA based catechin hydrate nanoparticles used in targeting of lungs and cancer treatment10.1016/j.sjbs.2020.05.023 ↗
36. Modulating the properties of flow-assembled chitosan membranes in microfluidics with glutaraldehyde crosslinking10.1039/C9TB02527H ↗
37. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats10.2217/17435889.3.5.703 ↗
38. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction10.2217/nnm.16.5 ↗
39. In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin10.2147/IJN.S213836 ↗
40. Nanoparticles Made From Xyloglucan-Block-Polycaprolactone Copolymers: Safety Assessment for Drug Delivery10.1093/toxsci/kfv114 ↗
41. Hemolysis of Human Erythrocytes by Argovit AgNPs from Healthy and Diabetic Donors: An In Vitro Study10.3390/ma14112792 ↗
42. In-Vitro Biocompatibility and Hemocompatibility Study of New PET Copolyesters Intended for Heart Assist Devices10.3390/polym12122857 ↗
43. S.Y. Eilleia, M.E. Soliman, S. Mansour, S.G. A, Novel technique of insulin loading into porous carriers for oral delivery, Asian J. Pharm. Sci. 13(4) (2018) 297–309.10.1016/j.ajps.2018.03.003 ↗
44. Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic - A STAT3 Dimerization Blocker10.2147/IJN.S337093 ↗
45. Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery10.3390/pharmaceutics13101590 ↗
46. Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines10.1016/j.sjbs.2021.05.025 ↗
47. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism Combinations, and Clinical Outcome10.3389/fphar.2017.00561 ↗
48. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model10.1016/j.cellimm.2021.104423 ↗
49. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity10.1038/cddis.2017.67 ↗